Roche’s AI CGM solution poised to revolutionise diabetes management with CE marking: GlobalData

Roche recently announced that its artificial intelligence (AI)-enabled continuous glucose monitoring (CGM) solution received the CE mark, signalling a significant advancement in diabetes management. With the CE mark, Roche’s innovative solution is poised to revolutionise diabetes management and enhance patient care, says GlobalData.

According to GlobalData, the AI market in the medical devices industry will surpass $1.2 billion by 2027, growing at a compound annual growth rate (CAGR) of 29.1 per cent during 2023-2027. Furthermore, GlobalData anticipates that the market for AI platforms across the entire healthcare sector will rise to $4.3 billion by 2024, up from $1.5 billion in 2019.

Graysen Vigneux, Medical Analyst at GlobalData, states, “AI is poised to become a significant driver of innovation in medical devices. AI-enabled CGM solutions offer critical advantages over traditional glucose monitoring methods, including real-time data, predictive analytics, and improved patient compliance.”

Roche’s solution integrates advanced AI with CGM technology, providing patients with real-time insights and predictive alerts. This development aims to empower patients with diabetes to better manage their condition, reduce complications, and improve their quality of life.

The company’s innovation extends beyond this development. it has several other innovative products in the pipeline, including next-generation insulin delivery systems and advanced digital health platforms designed to offer comprehensive diabetes management solutions. These upcoming products aim to provide even more personalised and effective care for diabetes patients, further solidifying Roche’s leadership in the field of diabetes technology.

“The incorporation of AI into CGM technology is a pivotal advancement that enhances the accuracy and reliability of glucose monitoring. Roche’s achievement with the CE Mark demonstrates the significant progress being made in digital health, particularly in the management of chronic conditions like diabetes,” adds Vigneux.